ID   HCD2_HUMAN              Reviewed;         261 AA.
AC   Q99714; Q5H927; Q6IBS9; Q8TCV9; Q96HD5;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   10-MAY-2017, entry version 191.
DE   RecName: Full=3-hydroxyacyl-CoA dehydrogenase type-2;
DE            EC=1.1.1.35;
DE   AltName: Full=17-beta-hydroxysteroid dehydrogenase 10;
DE            Short=17-beta-HSD 10;
DE            EC=1.1.1.51;
DE   AltName: Full=3-hydroxy-2-methylbutyryl-CoA dehydrogenase;
DE            EC=1.1.1.178;
DE   AltName: Full=3-hydroxyacyl-CoA dehydrogenase type II;
DE   AltName: Full=Endoplasmic reticulum-associated amyloid beta-peptide-binding protein;
DE   AltName: Full=Mitochondrial ribonuclease P protein 2;
DE            Short=Mitochondrial RNase P protein 2;
DE   AltName: Full=Short chain dehydrogenase/reductase family 5C member 1;
DE   AltName: Full=Short-chain type dehydrogenase/reductase XH98G2;
DE   AltName: Full=Type II HADH;
GN   Name=HSD17B10; Synonyms=ERAB, HADH2, MRPP2, SCHAD, SDR5C1, XH98G2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Brain;
RX   PubMed=9338779; DOI=10.1038/39522;
RA   Yan S.D., Fu J., Soto C., Chen X., Zhu H., Al-Mohanna F.,
RA   Collinson K., Zhu A., Stern E., Saido T., Tohyama M., Ogawa S.,
RA   Roher A., Stern D.;
RT   "An intracellular protein that binds amyloid-beta peptide and mediates
RT   neurotoxicity in Alzheimer's disease.";
RL   Nature 389:689-695(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Zhuchenko O.P., Wehnert M., Bailey J., Sun Z.S., Lee C.C.;
RL   Submitted (JAN-1997) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=9671743; DOI=10.1073/pnas.95.15.8709;
RA   Miller A.P., Willard H.F.;
RT   "Chromosomal basis of X chromosome inactivation: identification of a
RT   multigene domain in Xp11.21-p11.22 that escapes X inactivation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:8709-8714(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), AND CATALYTIC
RP   ACTIVITY.
RC   TISSUE=Brain;
RX   PubMed=9553139; DOI=10.1074/jbc.273.17.10741;
RA   He X.Y., Schulz H., Yang S.Y.;
RT   "A human brain L-3-hydroxyacyl-coenzyme A dehydrogenase is identical
RT   to an amyloid beta-peptide-binding protein involved in Alzheimer's
RT   disease.";
RL   J. Biol. Chem. 273:10741-10746(1998).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Brain, and Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 51-246.
RA   Deininger M.H., Meyermann R., Schluesener H.J.;
RT   "Expression, release and induction of endoplasmic reticulum-associated
RT   amyloid beta-binding protein in brain disease.";
RL   Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=12917011; DOI=10.1042/BJ20030877;
RA   Shafqat N., Marschall H.U., Filling C., Nordling E., Wu X.Q.,
RA   Bjork L., Thyberg J., Martensson E., Salim S., Jornvall H.,
RA   Oppermann U.;
RT   "Expanded substrate screenings of human and Drosophila type 10 17beta-
RT   hydroxysteroid dehydrogenases (HSDs) reveal multiple specificities in
RT   bile acid and steroid hormone metabolism: characterization of
RT   multifunctional 3alpha/7alpha/7beta/17beta/20beta/21-HSD.";
RL   Biochem. J. 376:49-60(2003).
RN   [11]
RP   INVOLVEMENT IN MRXS10.
RX   PubMed=17236142; DOI=10.1086/511527;
RA   Lenski C., Kooy R.F., Reyniers E., Loessner D., Wanders R.J.A.,
RA   Winnepenninckx B., Hellebrand H., Engert S., Schwartz C.E., Meindl A.,
RA   Ramser J.;
RT   "The reduced expression of the HADH2 protein causes X-linked mental
RT   retardation, choreoathetosis, and abnormal behavior.";
RL   Am. J. Hum. Genet. 80:372-377(2007).
RN   [12]
RP   INVOLVEMENT IN MRX17.
RX   PubMed=18252223; DOI=10.1016/j.ajhg.2007.11.002;
RA   Froyen G., Corbett M., Vandewalle J., Jarvela I., Lawrence O.,
RA   Meldrum C., Bauters M., Govaerts K., Vandeleur L., Van Esch H.,
RA   Chelly J., Sanlaville D., van Bokhoven H., Ropers H.-H.,
RA   Laumonnier F., Ranieri E., Schwartz C.E., Abidi F., Tarpey P.S.,
RA   Futreal P.A., Whibley A., Raymond F.L., Stratton M.R., Fryns J.-P.,
RA   Scott R., Peippo M., Sipponen M., Partington M., Mowat D., Field M.,
RA   Hackett A., Marynen P., Turner G., Gecz J.;
RT   "Submicroscopic duplications of the hydroxysteroid dehydrogenase
RT   HSD17B10 and the E3 ubiquitin ligase HUWE1 are associated with mental
RT   retardation.";
RL   Am. J. Hum. Genet. 82:432-443(2008).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY, FUNCTION, INTERACTION WITH
RP   KIAA0391 AND TRMT10C, AND SUBCELLULAR LOCATION.
RX   PubMed=18984158; DOI=10.1016/j.cell.2008.09.013;
RA   Holzmann J., Frank P., Loeffler E., Bennett K.L., Gerner C.,
RA   Rossmanith W.;
RT   "RNase P without RNA: identification and functional reconstitution of
RT   the human mitochondrial tRNA processing enzyme.";
RL   Cell 135:462-474(2008).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [16]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) IN COMPLEX WITH NAD.
RX   PubMed=15342248; DOI=10.1016/j.jmb.2004.07.071;
RA   Kissinger C.R., Rejto P.A., Pelletier L.A., Thomson J.A.,
RA   Showalter R.E., Abreo M.A., Agree C.S., Margosiak S., Meng J.J.,
RA   Aust R.M., Vanderpool D., Li B., Tempczyk-Russell A.,
RA   Villafranca J.E.;
RT   "Crystal structure of human ABAD/HSD10 with a bound inhibitor:
RT   implications for design of Alzheimer's disease therapeutics.";
RL   J. Mol. Biol. 342:943-952(2004).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS).
RX   PubMed=15087549; DOI=10.1126/science.1091230;
RA   Lustbader J.W., Cirilli M., Lin C., Xu H.W., Takuma K., Wang N.,
RA   Caspersen C., Chen X., Pollak S., Chaney M., Trinchese F., Liu S.,
RA   Gunn-Moore F., Lue L.-F., Walker D.G., Kuppusamy P., Zewier Z.L.,
RA   Arancio O., Stern D., Yan S.-S., Wu H.;
RT   "ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's
RT   disease.";
RL   Science 304:448-452(2004).
RN   [19]
RP   VARIANTS MHBD DEFICIENCY VAL-122 AND CYS-130.
RX   PubMed=12696021; DOI=10.1086/375116;
RA   Ofman R., Ruiter J.P.N., Feenstra M., Duran M., Poll-The B.T.,
RA   Zschocke J., Ensenauer R., Lehnert W., Sass J.O., Sperl W.,
RA   Wanders R.J.A.;
RT   "2-methyl-3-hydroxybutyryl-CoA dehydrogenase deficiency is caused by
RT   mutations in the HADH2 gene.";
RL   Am. J. Hum. Genet. 72:1300-1307(2003).
RN   [20]
RP   VARIANTS MHBD DEFICIENCY CYS-130 AND SER-247, AND CHARACTERIZATION OF
RP   VARIANT MHBD DEFICIENCY SER-247.
RX   PubMed=16148061; DOI=10.1203/01.pdr.0000176916.94328.cd;
RA   Perez-Cerda C., Garcia-Villoria J., Ofman R., Sala P.R., Merinero B.,
RA   Ramos J., Garcia-Silva M.T., Beseler B., Dalmau J., Wanders R.J.A.,
RA   Ugarte M., Ribes A.;
RT   "2-methyl-3-hydroxybutyryl-CoA dehydrogenase (MHBD) deficiency: an X-
RT   linked inborn error of isoleucine metabolism that may mimic a
RT   mitochondrial disease.";
RL   Pediatr. Res. 58:488-491(2005).
RN   [21]
RP   ERRATUM.
RA   Perez-Cerda C., Garcia-Villoria J., Ofman R., Sala P.R., Merinero B.,
RA   Ramos J., Garcia-Silva M.T., Beseler B., Dalmau J., Wanders R.J.,
RA   Ugarte M., Ribes A.;
RL   Pediatr. Res. 59:162-162(2006).
CC   -!- FUNCTION: Functions in mitochondrial tRNA maturation. Part of
CC       mitochondrial ribonuclease P, an enzyme composed of MRPP1/TRMT10C,
CC       MRPP2/HSD17B10 and MRPP3/KIAA0391, which cleaves tRNA molecules in
CC       their 5'-ends. Catalyzes the beta-oxidation at position 17 of
CC       androgens and estrogens and has 3-alpha-hydroxysteroid
CC       dehydrogenase activity with androsterone. Catalyzes the third step
CC       in the beta-oxidation of fatty acids. Carries out oxidative
CC       conversions of 7-alpha-OH and 7-beta-OH bile acids. Also exhibits
CC       20-beta-OH and 21-OH dehydrogenase activities with C21 steroids.
CC       By interacting with intracellular amyloid-beta, it may contribute
CC       to the neuronal dysfunction associated with Alzheimer disease
CC       (AD). {ECO:0000269|PubMed:12917011, ECO:0000269|PubMed:18984158,
CC       ECO:0000269|PubMed:9338779}.
CC   -!- CATALYTIC ACTIVITY: (S)-3-hydroxyacyl-CoA + NAD(+) = 3-oxoacyl-CoA
CC       + NADH.
CC   -!- CATALYTIC ACTIVITY: (2S,3S)-3-hydroxy-2-methylbutanoyl-CoA +
CC       NAD(+) = 2-methylacetoacetyl-CoA + NADH.
CC   -!- CATALYTIC ACTIVITY: Testosterone + NAD(P)(+) = androst-4-ene-3,17-
CC       dione + NAD(P)H.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=25.7 uM for acetoacetyl-CoA (in the presence of 0.2 mM NADH,
CC         at pH 7.0 and 25 degrees Celsius) {ECO:0000269|PubMed:12917011};
CC         KM=85.2 uM for beta-hydroxybutyryl-CoA (in the presence of 1 mM
CC         NAD, at pH 9.3 and 25 degrees Celsius)
CC         {ECO:0000269|PubMed:12917011};
CC         KM=41 uM for androsterone (in the presence of 1 mM NAD, at pH
CC         9.3 and 25 degrees Celsius) {ECO:0000269|PubMed:12917011};
CC         KM=5 uM for 5-alpha-pregnan-20-beta-ol-3-one (in the presence of
CC         1 mM NAD, at pH 9.3 and 25 degrees Celsius)
CC         {ECO:0000269|PubMed:12917011};
CC         KM=219 uM for isoursodeoxycholic acid (in the presence of 1 mM
CC         NAD, at pH 9.3 and 25 degrees Celsius)
CC         {ECO:0000269|PubMed:12917011};
CC         KM=36.4 uM for chenodeoxycholic acid (in the presence of 1 mM
CC         NAD, at pH 9.3 and 25 degrees Celsius)
CC         {ECO:0000269|PubMed:12917011};
CC         KM=1.7 uM for dehydrocorticosterone (in the presence of 1 mM
CC         NAD, at pH 9.3 and 25 degrees Celsius)
CC         {ECO:0000269|PubMed:12917011};
CC         KM=30.6 uM for NADH (in the presence of acetoacetyl-CoA, at pH
CC         7.0 and 25 degrees Celsius) {ECO:0000269|PubMed:12917011};
CC         KM=42.3 uM for NAD (in the presence of beta-hydroxybutyryl-CoA,
CC         at pH 9.3 and 25 degrees Celsius) {ECO:0000269|PubMed:12917011};
CC       pH dependence:
CC         Optimum pH is 9.3 for the dehydrogenase reaction at 25 degrees
CC         Celsius, and 7.0 for the reductase reaction at 25 degrees
CC         Celsius. {ECO:0000269|PubMed:12917011};
CC   -!- SUBUNIT: Homotetramer (By similarity). Interacts with
CC       MRPP1/TRMT10C and MRPP3/KIAA0391. {ECO:0000250,
CC       ECO:0000269|PubMed:15342248, ECO:0000269|PubMed:18984158}.
CC   -!- INTERACTION:
CC       P05067:APP; NbExp=4; IntAct=EBI-79964, EBI-77613;
CC       Q7L0Y3:TRMT10C; NbExp=4; IntAct=EBI-79964, EBI-2107046;
CC   -!- SUBCELLULAR LOCATION: Mitochondrion {ECO:0000269|PubMed:12917011,
CC       ECO:0000269|PubMed:18984158}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q99714-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q99714-2; Sequence=VSP_007830;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed in normal tissues but
CC       is overexpressed in neurons affected in AD.
CC       {ECO:0000269|PubMed:9338779}.
CC   -!- DISEASE: 2-methyl-3-hydroxybutyryl-CoA dehydrogenase deficiency
CC       (MHBD deficiency) [MIM:300438]: A disorder that leads to
CC       neurological abnormalities, including psychomotor retardation and,
CC       in virtually all patients, loss of mental and motor skills.
CC       {ECO:0000269|PubMed:12696021, ECO:0000269|PubMed:16148061}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Mental retardation, X-linked, syndromic, 10 (MRXS10)
CC       [MIM:300220]: A disorder characterized by significantly below
CC       average general intellectual functioning associated with
CC       impairments in adaptive behavior and manifested during the
CC       developmental period. MRXS10 patients manifest mild mental
CC       retardation, choreoathetosis and abnormal behavior.
CC       {ECO:0000269|PubMed:17236142}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Mental retardation, X-linked 17 (MRX17) [MIM:300705]: A
CC       disorder characterized by significantly below average general
CC       intellectual functioning associated with impairments in adaptive
CC       behavior and manifested during the developmental period.
CC       Intellectual deficiency is the only primary symptom of non-
CC       syndromic X-linked mental retardation, while syndromic mental
CC       retardation presents with associated physical, neurological and/or
CC       psychiatric manifestations. {ECO:0000269|PubMed:18252223}.
CC       Note=The gene represented in this entry is involved in disease
CC       pathogenesis. A chromosomal microduplication involving HSD17B10
CC       and HUWE1 has been found in patients with mental retardation.
CC   -!- SIMILARITY: Belongs to the short-chain dehydrogenases/reductases
CC       (SDR) family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U96132; AAC51812.1; -; mRNA.
DR   EMBL; U73514; AAB68958.1; -; mRNA.
DR   EMBL; AF069134; AAC39900.1; -; mRNA.
DR   EMBL; AF035555; AAC15902.1; -; mRNA.
DR   EMBL; AF037438; AAC16419.1; -; Genomic_DNA.
DR   EMBL; CR456723; CAG33004.1; -; mRNA.
DR   EMBL; Z97054; CAI42652.1; -; Genomic_DNA.
DR   EMBL; Z97054; CAI42653.1; -; Genomic_DNA.
DR   EMBL; CH471154; EAW93157.1; -; Genomic_DNA.
DR   EMBL; CH471154; EAW93158.1; -; Genomic_DNA.
DR   EMBL; BC000372; AAH00372.1; -; mRNA.
DR   EMBL; BC008708; AAH08708.1; -; mRNA.
DR   EMBL; AY092415; AAM18189.1; -; mRNA.
DR   CCDS; CCDS14354.1; -. [Q99714-1]
DR   CCDS; CCDS35300.1; -. [Q99714-2]
DR   RefSeq; NP_001032900.1; NM_001037811.2. [Q99714-2]
DR   RefSeq; NP_004484.1; NM_004493.2. [Q99714-1]
DR   UniGene; Hs.171280; -.
DR   PDB; 1F67; Model; -; A=1-261.
DR   PDB; 1SO8; X-ray; 2.30 A; A=1-261.
DR   PDB; 1U7T; X-ray; 2.00 A; A/B/C/D=1-261.
DR   PDB; 2O23; X-ray; 1.20 A; A/B=1-261.
DR   PDBsum; 1F67; -.
DR   PDBsum; 1SO8; -.
DR   PDBsum; 1U7T; -.
DR   PDBsum; 2O23; -.
DR   ProteinModelPortal; Q99714; -.
DR   SMR; Q99714; -.
DR   BioGrid; 109278; 243.
DR   IntAct; Q99714; 26.
DR   MINT; MINT-3059664; -.
DR   STRING; 9606.ENSP00000168216; -.
DR   ChEMBL; CHEMBL4159; -.
DR   DrugBank; DB00157; NADH.
DR   SwissLipids; SLP:000000787; -.
DR   iPTMnet; Q99714; -.
DR   PhosphoSitePlus; Q99714; -.
DR   SwissPalm; Q99714; -.
DR   BioMuta; HSD17B10; -.
DR   DMDM; 2492759; -.
DR   REPRODUCTION-2DPAGE; IPI00017726; -.
DR   REPRODUCTION-2DPAGE; Q99714; -.
DR   UCD-2DPAGE; Q99714; -.
DR   EPD; Q99714; -.
DR   MaxQB; Q99714; -.
DR   PaxDb; Q99714; -.
DR   PeptideAtlas; Q99714; -.
DR   PRIDE; Q99714; -.
DR   TopDownProteomics; Q99714-1; -. [Q99714-1]
DR   TopDownProteomics; Q99714-2; -. [Q99714-2]
DR   DNASU; 3028; -.
DR   Ensembl; ENST00000168216; ENSP00000168216; ENSG00000072506. [Q99714-1]
DR   Ensembl; ENST00000375304; ENSP00000364453; ENSG00000072506. [Q99714-2]
DR   GeneID; 3028; -.
DR   KEGG; hsa:3028; -.
DR   UCSC; uc004dsl.2; human. [Q99714-1]
DR   CTD; 3028; -.
DR   DisGeNET; 3028; -.
DR   GeneCards; HSD17B10; -.
DR   HGNC; HGNC:4800; HSD17B10.
DR   HPA; HPA001432; -.
DR   MalaCards; HSD17B10; -.
DR   MIM; 300220; phenotype.
DR   MIM; 300256; gene.
DR   MIM; 300438; phenotype.
DR   MIM; 300705; phenotype.
DR   neXtProt; NX_Q99714; -.
DR   OpenTargets; ENSG00000072506; -.
DR   Orphanet; 85295; HSD10 disease, atypical type.
DR   Orphanet; 391428; HSD10 disease, infantile type.
DR   Orphanet; 391457; HSD10 disease, neonatal type.
DR   PharmGKB; PA162391638; -.
DR   eggNOG; KOG1199; Eukaryota.
DR   eggNOG; ENOG410XNNW; LUCA.
DR   GeneTree; ENSGT00760000118868; -.
DR   HOVERGEN; HBG002145; -.
DR   InParanoid; Q99714; -.
DR   KO; K08683; -.
DR   OMA; LMGLVNC; -.
DR   OrthoDB; EOG091G0G9O; -.
DR   PhylomeDB; Q99714; -.
DR   TreeFam; TF354307; -.
DR   BioCyc; MetaCyc:HS01071-MONOMER; -.
DR   BRENDA; 1.1.1.178; 2681.
DR   BRENDA; 1.1.1.35; 2681.
DR   Reactome; R-HSA-6785470; tRNA processing in the mitochondrion.
DR   Reactome; R-HSA-6787450; tRNA modification in the mitochondrion.
DR   Reactome; R-HSA-70895; Branched-chain amino acid catabolism.
DR   Reactome; R-HSA-8868766; rRNA processing in the mitochondrion.
DR   SABIO-RK; Q99714; -.
DR   ChiTaRS; HSD17B10; human.
DR   EvolutionaryTrace; Q99714; -.
DR   GeneWiki; HSD17B10; -.
DR   GenomeRNAi; 3028; -.
DR   PRO; PR:Q99714; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; ENSG00000072506; -.
DR   CleanEx; HS_HSD17B10; -.
DR   ExpressionAtlas; Q99714; baseline and differential.
DR   Genevisible; Q99714; HS.
DR   GO; GO:0005737; C:cytoplasm; TAS:ProtInc.
DR   GO; GO:0005759; C:mitochondrial matrix; TAS:Reactome.
DR   GO; GO:0030678; C:mitochondrial ribonuclease P complex; TAS:CAFA.
DR   GO; GO:0005739; C:mitochondrion; IDA:CAFA.
DR   GO; GO:0005886; C:plasma membrane; TAS:ProtInc.
DR   GO; GO:0047015; F:3-hydroxy-2-methylbutyryl-CoA dehydrogenase activity; IEA:UniProtKB-EC.
DR   GO; GO:0003857; F:3-hydroxyacyl-CoA dehydrogenase activity; IDA:CAFA.
DR   GO; GO:0008709; F:cholate 7-alpha-dehydrogenase activity; TAS:ProtInc.
DR   GO; GO:0003723; F:RNA binding; IDA:UniProtKB.
DR   GO; GO:0030283; F:testosterone dehydrogenase [NAD(P)] activity; IEA:UniProtKB-EC.
DR   GO; GO:0009083; P:branched-chain amino acid catabolic process; TAS:Reactome.
DR   GO; GO:0006629; P:lipid metabolic process; TAS:ProtInc.
DR   GO; GO:0070901; P:mitochondrial tRNA methylation; TAS:Reactome.
DR   GO; GO:0090646; P:mitochondrial tRNA processing; TAS:Reactome.
DR   InterPro; IPR016040; NAD(P)-bd_dom.
DR   InterPro; IPR020904; Sc_DH/Rdtase_CS.
DR   InterPro; IPR002347; SDR_fam.
DR   Pfam; PF00106; adh_short; 1.
DR   PRINTS; PR00081; GDHRDH.
DR   PRINTS; PR00080; SDRFAMILY.
DR   SUPFAM; SSF51735; SSF51735; 1.
DR   PROSITE; PS00061; ADH_SHORT; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing;
KW   Chromosomal rearrangement; Complete proteome; Disease mutation;
KW   Mental retardation; Mitochondrion; NAD; Oxidoreductase;
KW   Reference proteome; tRNA processing.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:25944712}.
FT   CHAIN         2    261       3-hydroxyacyl-CoA dehydrogenase type-2.
FT                                /FTId=PRO_0000054810.
FT   NP_BIND      12     41       NAD. {ECO:0000269|PubMed:15342248}.
FT   ACT_SITE    168    168       Proton acceptor.
FT   BINDING     155    155       Substrate.
FT   BINDING     172    172       NAD. {ECO:0000269|PubMed:15342248}.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000244|PubMed:25944712}.
FT   MOD_RES      53     53       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:O08756}.
FT   MOD_RES      53     53       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:O08756}.
FT   MOD_RES      69     69       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:O08756}.
FT   MOD_RES      99     99       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:O08756}.
FT   MOD_RES     105    105       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:O08756}.
FT   MOD_RES     212    212       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:O08756}.
FT   MOD_RES     212    212       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:O08756}.
FT   VAR_SEQ     191    199       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_007830.
FT   VARIANT     122    122       L -> V (in MHBD deficiency;
FT                                dbSNP:rs28935476).
FT                                {ECO:0000269|PubMed:12696021}.
FT                                /FTId=VAR_015987.
FT   VARIANT     130    130       R -> C (in MHBD deficiency;
FT                                dbSNP:rs28935475).
FT                                {ECO:0000269|PubMed:12696021,
FT                                ECO:0000269|PubMed:16148061}.
FT                                /FTId=VAR_015988.
FT   VARIANT     247    247       N -> S (in MHBD deficiency; intermediate
FT                                enzyme activity; dbSNP:rs122461163).
FT                                {ECO:0000269|PubMed:16148061}.
FT                                /FTId=VAR_032093.
FT   STRAND       12     16       {ECO:0000244|PDB:2O23}.
FT   TURN         17     19       {ECO:0000244|PDB:2O23}.
FT   HELIX        21     32       {ECO:0000244|PDB:2O23}.
FT   STRAND       36     41       {ECO:0000244|PDB:2O23}.
FT   HELIX        47     54       {ECO:0000244|PDB:2O23}.
FT   STRAND       58     62       {ECO:0000244|PDB:2O23}.
FT   HELIX        68     82       {ECO:0000244|PDB:2O23}.
FT   STRAND       87     90       {ECO:0000244|PDB:2O23}.
FT   STRAND      100    102       {ECO:0000244|PDB:2O23}.
FT   TURN        103    106       {ECO:0000244|PDB:2O23}.
FT   HELIX       111    121       {ECO:0000244|PDB:2O23}.
FT   HELIX       123    136       {ECO:0000244|PDB:2O23}.
FT   STRAND      148    153       {ECO:0000244|PDB:2O23}.
FT   HELIX       157    160       {ECO:0000244|PDB:2O23}.
FT   HELIX       166    186       {ECO:0000244|PDB:2O23}.
FT   HELIX       187    189       {ECO:0000244|PDB:2O23}.
FT   STRAND      191    198       {ECO:0000244|PDB:2O23}.
FT   HELIX       204    208       {ECO:0000244|PDB:1U7T}.
FT   HELIX       216    219       {ECO:0000244|PDB:2O23}.
FT   STRAND      222    224       {ECO:0000244|PDB:2O23}.
FT   HELIX       230    242       {ECO:0000244|PDB:2O23}.
FT   STRAND      250    254       {ECO:0000244|PDB:2O23}.
SQ   SEQUENCE   261 AA;  26923 MW;  9E74F242E3E6FEF1 CRC64;
     MAAACRSVKG LVAVITGGAS GLGLATAERL VGQGASAVLL DLPNSGGEAQ AKKLGNNCVF
     APADVTSEKD VQTALALAKG KFGRVDVAVN CAGIAVASKT YNLKKGQTHT LEDFQRVLDV
     NLMGTFNVIR LVAGEMGQNE PDQGGQRGVI INTASVAAFE GQVGQAAYSA SKGGIVGMTL
     PIARDLAPIG IRVMTIAPGL FGTPLLTSLP EKVCNFLASQ VPFPSRLGDP AEYAHLVQAI
     IENPFLNGEV IRLDGAIRMQ P
//
